Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my ...

Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...

Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...

Sam Finn, a senior research associate at Zymo Research working with the Oncology Diagnostic Team, helped to host this interactive game booth at the “BioFestival” on Tuesday.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. The ...

SAN CARLOS, Calif. - Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on novel cancer treatments, announced today the appointment of Dan Kirby (NYSE:KEX) as Chief ...

(HT) “We were working on sensor technology and I was the person with the biotech background. There were reports about the sense of smell that dogs possess and how it was possible for them to ...

They show that he plans to divest stock holdings, including stakes in biotech firms CRISPR Therapeutics AG and Dragonfly Therapeutics. He’s also stepping down from roles at his law firm and at ...

A requisite majority of H-class shareholders did not approve the buyout, the companies said. "The proposed privatisation of the Company (Henlius) will not proceed and the listing of the H Shares ...

Primarily, Ascentage hopes to leverage the IPO proceeds to advance its pipeline. Around $50 million to $60 million, for instance, will help the biotech pursue approval for its BCL-2 blocker ...